Genetic basis of procoagulant and fibrinolytic perioperative adverse events

Best Practice and Research: Clinical Anaesthesiology

Volumn 15, Issue 2, 2001, Pages 195-211

  Spiess, Bruce D ^a   Chandler, Wayne ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adverse outcomes; Fibrinolysis; Genetics; Heart surgery; Hypercoagulability; Surgery

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; PROTEIN C; PROTEIN S;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BLEEDING DISORDER; CORONARY ARTERY THROMBOSIS; FIBRINOLYSIS; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERCOAGULABILITY; MINIMALLY INVASIVE SURGERY; MORBIDITY; MORTALITY; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; STROKE; SURGICAL RISK; SURGICAL STRESS; THORAX SURGERY; THROMBOCYTOSIS; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

EID: 0034907709     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1053/bean.2001.0152     Document Type: Article

References (67)

1. Aristotle and the human genome project
2. Role of molecular biology in identifying individuals at risk for sudden cardiac death
3. Challenges for protein chemical synthesis in the 21st century: Bridging genomics and proteonics
4. Stress response in orthopedics and trauma in paediatrics: General versus regional anesthesia
5. Stress-free cardiac anaesthesia
6. Adverse cerebral outcomes after coronary bypass surgery
7. Variability in transfusion practice for coronary artery surgery persists despite national consensus guidelines - A 24 institution study
8. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery
9. A contemporary view of coagulation
10. Activation of human blood coagulation factor XI independent of factor XII: Factor XI is activated by thrombin and XIa in the presence of negatively charged surfaces
11. Factor XI activation in a revised model of blood coagulation
12. Mathematical analysis of activation thresholds in enzyme-catalyzed positive feedbacks; Application to the feedbacks of blood coagulation
13. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass
14. Thrombosis in antithrombin III-deficient persons; Report of a large kindred and literature review
15. A novel nonsense mutation in the antithrombin III gene (C6S-4-stop) causing recurrent venous thrombosis
16. Inherited antithrombin III deficiency in the neonate
17. Congenital antithrombin III deficiency
18. A molecular basis of inherited antithrombin deficiency
19. Mortality in hereditary antithrombin III deficiency: 1830-1989
20. Clinical manifestations and management of inherited thrombophelia: Retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C and protein S
21. Molecular basis of antithrombin deficiency in French families: Identification of seven novel mutations in the antithrombin gene
22. Major structural defects in the antithrombin gene in four families with type I antithrombin deficiency - Partial/complete deletions and rearrangement of the antithrombin gene
23. Mutation in factor V associated with resistance to activated protein C
24. Genetic factors associated with thrombosis in pregnancy in a United States population
25. Factor V Leiden: The venous thrombotic risk
26. The high prevalence of the factor V Leiden mutation in central European inflammatory bowel disease patients
27. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)
28. Severe preeclampsia and high frequency of genetic thrombophilic mutations
29. Mutation in factor V associated with resistance to activated protein C
30. Deficiency of protein C in congenital thrombotic disease
31. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred
32. Inherited protein C deficiency and coumarin responsive relapsing purpura fulminans in a newborn infant
33. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn
34. Molecular and cellular biology of blood coagulation
35. Platelets and their interactions
36. Changes of hemostatic molecular markers after gynecological surgery
37. Course of molecular hemostatic markers during and after different surgical procedures
38. Hemorheological profile in chronic venous insufficiency after surgery
39. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
40. Coagulation and inflammation polymorphisms: Impact on cardiovascular outcomes
41. Hereditary dysfibrinogenemia in a patient with thrombotic disease
42. A new type of congenital dysfibrinogenemia with defective fibrin lysis-Dusart syndrome; Possible relations to thrombosis
43. Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris
44. Genetic variation at fibrinogen loci and plasma fibrinogen levels
45. European Atherosclerosis Research Study; Genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe: Evidence for gender-genotype-environment interactions
46. Fibrinogen plasma levels in an apparently healthy general population: Relation to environmental and genetic determinants
47. The acute rise in plasma fibrinogen concentration with exercise is influenced by the G-453-A polymorphism of the beta-fibrinogen gene
48. Impact of polymorphisms in the alpha and beta fibrinogen gene and plasma fibrinogen concentrations of coronary heart disease patients
49. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study
50. Genetic variations of platelet glycoprotein receptors and risk of stroke in young women
51. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
52. The PI (A2) polymorphism of integrin beta 3 enhances outside-in signaling and adhesion functions
53. The human fibrinolytic system
54. Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction
55. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene
56. Polymorphism of platelet membrane IIIa: Human platelet antigen 1b(HPA-1b/P1A2) is an inherited risk factor for premature myocardial infarction in coronary artery disease
57. Fibrinolysis and risk of coronary artery disease
58. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
59. The 4G/5G genetic polymorphism in the promotor region of the plasminogen activator inhibitor-1 (PAI-1) associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
60. Tissue plasminogen activator and the risk of myocardial infarction, the Rotterdam Study
61. Angiotensin converting enzyme insertion/deletion polymorphism is associated with plasma antigen levels of plasminogen activator inhibitor-1 in healthy Japanese population
62. Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease
63. The increase of plasminogen activator inhibitor activity is associated with graft occlusion in patients undergoing aorto-coronary artery bypass surgery
64. Effects of epidural anesthesia and analgesia after major vascular surgery
65. The effects of different anesthetic regimens on fibrinolysis and the development of postoperative arterial thrombosis. Perioperative Ischemia Randomized Anesthesia Trial Study Group
66. Con: Regional anesthesia is not better than general anesthesia for lower extremity revascularization